Other names: KIP1; P27KIP1 Location: 12p13 Local order: centromere -CDNK1B -ETV6 -PRB -KCNA5 -CACNL1A1 -telomere. 
Protein
Description 198 amino-acids; 22 kDa; homology to WAF1, limited to a 60 amino acid segment in the N-term half of the protein (residues 28-88); putative bipartite nuclear localization signal near the C-term (153-169); C-term extension of 23 amino acids that contains a consensus Cdc2 phosphorylation site.
Expression
Expressed in all tissues tested; high levels in skeletal muscle, low levels in liver and kidney.
Localisation
Nuclear.
Function
-CDKN1B is a negative regulator implicated in G1 arrest mediated by TGFb, cell-cell contact, agents that elevate cyclic AMP and rapamycin; CDKN1B binds to and acts as a stoichiometric inhibitor of G1-cyclincyclin dependent kinase complexes (cyclin E-Cdk2, cyclin A-Cdk2, cyclin D-Cdk4 (restriction point)), controlling G1 to S phase transition or exit from the cell cycle; CDKN1B coordinates the varied inputs from the extracellular environment; post-translational ubiquitin-mediated proteasomal proteolysis represents the major regulatory influence of CDKN1B protein level.
-in CDKN1B knockout mouse, CDKN1B defect causes multi-organ hyperplasia with features of gigantism, abnormalities of thymus, retina, pituitary, adrenal glands and gonadal organs (ovulatory defect and female sterility).
Homology
Cip1/WAF1.
Implicated in

Haematological malignancies
Note: hemizygous interstitial deletion is found in 10% of cytogenetically normal ANLL; monoallelic deletion found in 5% ANLL cases, but not described in ALL; no case so far of CDKN1B mutations in leukemia samples.
CDKN1B (cyclin-dependent kinase inhibitor 1 B)
Bilhou-Nabera C Atlas Genet Cytogenet Oncol Haematol. 1998; 2(4) Primary breast cancers Prognosis A low nuclear expression of CDKN1B protein is a significant predictor of poor disease-free survival; in contrary, high level of CDKN1B protein expression combined with low level expression of its target (cyclin E-Cdk2) correlates with about 90% 10-yr overall survival in the lymph node-negative subgroup.
Primary colorectal carcinomas
Prognosis CDKN1B is an independent prognostic marker: low levels are significantly correlated with a poor prognosis.
